In 2018, the global 12-month-prevalence of cannabis use was estimated at 3·9% [1]. Based on surveys from 2015 to 2020, it is estimated that 15·4% of EU inhabitants aged 15 to 35 used cannabis in the previous year [2]. Occasional and more so heavy use of cannabis is associated with a number of adverse outcomes, including cannabis use disorder (CUD; [3]) and an increased risk of psychosis [4], [5], [6], [7], acute cognitive impairment [8,9] as well as other outcomes such as motor vehicle accidents [10], respiratory problems, testicular cancer [11] and lower birthweight of offspring (for current reviews, see [11], [12], [13], [14], [15]). In 2019, the Global Burden of Disease (GBD) study estimated that 0·6% of the European population met criteria for CUD, resulting in 158,000,000 disability adjusted life years [16]. In addition, there are indications that cannabinoids are genotoxic and epigenotoxic with yet to determined multigenerational implications on population health [17].
